研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Zhejiang University[3]First Affiliated Hospital, Sun Yat-Sen University[4]The First Affiliated Hospital of Zhengzhou University[5]Changhai Hospital[6]The First Affiliated Hospital of Sun Yat-sen University.,Guangzhou,Guangdong,China[7]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[8]The First Affiliated Hospital of Zhejiang University,Hangzhou,China[9]Changhai Hospital affiliated to Naval Military Medical University,Shanghai,China
研究目的：
The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is: Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy? The transplant and follow-up data of participants will be retrospectively collected. Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.
